New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA® (teprotumumab-trbw) Comparable with Clinical Trial Observations

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced results from a post-marketing safety analysis of TEPEZZA (teprotumumab-trbw) for the treatment of Thyroid Eye Disease.